Results 51 to 60 of about 80,637 (252)

A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors

Journal for ImmunoTherapy of Cancer, 2018
Background Escalating healthcare costs are necessitating the practice of value-based oncology. It is crucial to critically evaluate the economic impact of influential but expensive therapies such as immune checkpoint inhibitors (ICIs).
Vivek Verma, Tanja Sprave, Waqar Haque, Charles B. Simone, Joe Y. Chang, James W. Welsh, Charles R. Thomas   +6 more
doaj   +1 more source

Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma

Respiratory Medicine Case Reports, 2020
Malignant pleural mesothelioma (MPM) is a rare and highly aggressive tumor. Nivolumab showed durable antitumor effect in patients with recurrent MPM and was approved for those patients in Japan in 2018.
Jun Sakakibara-Konishi, Mineyoshi Sato, Michiko Takimoto Sato, Kohei Kasahara, Masahiro Onozawa, Hidenori Mizugaki, Eiki Kikuchi, Hajime Asahina, Naofumi Shinagawa, Satoshi Konno   +9 more
doaj   +1 more source

A Synthetic Platform for Antibody Junctional Diversification Beyond Natural Constraints

Advanced Science, EarlyView.
ARESEC is a synthetic platform that reconstructs functional V(D)J recombination in HEK293T cells. By introducing RSS elements and co‐expressing RAG1/2 and TdT across all three antibody CDRs, it enables programmable junctional diversification and direct generation of high‐affinity variants targeting PD‐1/PD‐L1, overcoming the evolutionary constraints of
Wang Liu, Jun Yang, Yuhang Zhang, Xiaoli Xue   +3 more
wiley   +1 more source

Tissue‐Agnostic Cellular Morphometric Biomarkers for Risk‐Adapted Management Across Gastrointestinal Precancerous Lesions and Cancers

Advanced Science, EarlyView.
An interpretable, unsupervised artificial intelligence framework identifies a 13‐cellular morphometric biomarker (CMB) signature from routine H&E whole‐slide images. Validated across 2,602 patients, the fixed signature generalizes across colorectal, gastric, and esophageal tissues without retraining, stratifies prognosis and precancerous lesion risk ...
Pin Wang, Chengfei Jiang, April W. Mao, Qi Sun, Yijun Lu, Jingjing Wei, Jamie L. Inman, Susan E. Celniker, Antoine M. Snijders, David W. Threadgill, Allan Balmain, Bo Hang, Hang Chang, Lei Wang, Jian‐Hua Mao   +14 more
wiley   +1 more source

Enhancing Effector Jurkat Cell Activity and Increasing Cytotoxicity against A549 Cells Using Nivolumab as an Anti-PD-1 Agent Loaded on Gelatin Nanoparticles

Gels
The current research investigated the use of gelatin nanoparticles (GNPs) for enhancing the cytotoxic effects of nivolumab, an immune checkpoint inhibitor.
Dalia S. Ali, Heba A. Gad, Rania M. Hathout   +2 more
doaj   +1 more source

Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab

Thoracic Cancer, 2019
Background It remains unclear why radiation clinically provides a synergistic effect when combined with immune checkpoint inhibitors such as nivolumab. The purpose of our study was to retrospectively evaluate whether the therapeutic efficacy of nivolumab
Ou Yamaguchi, Kyoichi Kaira, Kosuke Hashimoto, Atsuto Mouri, Yu Miura, Ayako Shiono, Fuyumi Nishihara, Yoshitake Murayama, Shin‐ei Noda, Shingo Kato, Kunihiko Kobayashi, Hiroshi Kagamu   +11 more
doaj   +1 more source

The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies

Advanced Science, EarlyView.
This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang, Zhicheng Zhou, Xue Jiang, Zhenguang Du, Yangyang Zhan, Xinli Liu   +5 more
wiley   +1 more source

Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081

Journal for ImmunoTherapy of Cancer
Background For unresectable stage III non-small-cell lung cancer (NSCLC), the optimal duration and regimen of consolidation immunotherapy following chemoradiation is unknown.
Borys Hrinczenko, Jarushka Naidoo, Jason Chesney, Salma K Jabbour, Naomi Fujioka, Greg Durm, Apar Kishor Ganti, Hirva Mamdani, Mary Jo Fidler, Nasser H Hanna, Shadia Jalal, Ticiana A Leal, Sandra Althouse, Susan Perkins, Lawrence Feldman   +14 more
doaj   +1 more source

Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer

OncoImmunology, 2017
Nivolumab, an anti PD-1 checkpoint inhibitor has demonstrated efficacy in metastatic non-small-cell lung cancer (NSCLC) patients after failure to standard chemotherapy. Standard chemotherapy agents could promote antitumor immune response.
Courèche-Guillaume Kaderbhai, Corentin Richard, Jean David Fumet, Anne Aarnink, Sandra Ortiz-Cuaran, Maurice Pérol, Pascal Foucher, Bruno Coudert, Laure Favier, Aurélie Lagrange, Emeric Limagne, Romain Boidot, Sylvain Ladoire, Michel Poudenx, Marius Ilie, Paul Hofman, Pierre Saintigny, François Ghiringhelli   +17 more
doaj   +1 more source

Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data

, 2023
Yuntae Kim,1,2 Shun Yamamoto,1 Ken Kato1 1Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; 2Department of Gastroenterology, St.
Kato K, Yamamoto S, Kim Y
core